Regado and Tobira to merge to create leading NASH company

14 January 2015

The USA’s Regado Biosciences (Nasdaq: RGDO) and privately-held Tobira Therapeutics have entered into a definitive agreement under which Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction. The news sent Regado’s shares 45.4% higher to $1.25 in early trading this morning.

The merger will create a company focused on the development of novel treatments for liver and inflammatory diseases. Tobira's lead product, immunomodulator and anti-fibrotic agent cenicriviroc (CVC), received Fast Track designation and is currently in a Phase IIb trial in non-alcoholic steatohepatitis (NASH).

Last year, Regado announced the permanent termination of enrollment in its REGULATE-PCI Phase III trial for its lead program, Revolixys Kit, its lead product candidate. The decision was based on a recommendation from the trial's Data and Safety Monitoring Board (DSMB) and following a clinical hold on the study by the Food and Drug Administration.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK